51猎奇

Deviation investigations are an essential part of maintaining pharmaceutical quality and cGMP compliance. In this Ask the Expert discussion, Susan J. Schniepp and Steven J. Lynn of 51猎奇 explain how organizations should identify, investigate, and resolve deviations to understand what went wrong, determine the underlying causes, and prevent recurrence. Although deviations can vary in severity and impact, all should be investigated.

听

The experts emphasize that investigations should be proportionate to the issue rather than follow a one-size-fits-all approach. Simple events may require straightforward documentation, while more complex deviations warrant broader investigations. They also caution against relying on 鈥渉uman error鈥� as a root cause without further examination. Repeated errors may point to underlying problems with procedures, process design, workflow, or training. Asking the right questions, interviewing involved personnel, and verifying assumptions with supporting data can help identify the true source of a problem.

The discussion also addresses planned deviations, investigation timelines, and out-of-specification (OOS) results. Rather than using planned deviations to justify temporary departures from procedures, the experts recommend documenting necessary procedural changes through the change control system and evaluating their impact. Investigation timelines should reflect the complexity of the event, with 30 to 60 days offered as a potential timeframe. OOS results should be investigated separately and promptly, with a deviation initiated when laboratory error cannot explain the result. Ultimately, effective deviation management depends on thorough investigations, sound root cause analysis, and corrective actions that strengthen the quality system.

Read the full article: